Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 23

Trial Status

Completed3

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT00136760Phase 2Completed
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
Schizophrenia and Disorders With Psychotic FeaturesTobacco Use Disorder
Principalinvestigator
NCT00218218Phase 2Completed
Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia
SchizophreniaSchizophrenia and Disorders With Psychotic FeaturesTobacco Use Disorder
Principalinvestigator
NCT00218231Phase 2Completed
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
SchizophreniaTobacco Use Disorder
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Elliot Stein, Ph.D.

National Institute on Drug Abuse (NIDA)

Related
20 trials

Shared therapeutic areas:

SchizophreniaTobacco Use Disorder

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score20%

Zhang-Jin Zhang, MMed, PhD

The University of Hong Kong

Related
11 trials

Shared therapeutic areas:

SchizophreniaSchizophrenia Spectrum and Other Psychotic Disorders
Similarity Score20%

Sanjeev Pathak, MD

Alkermes, Inc.

Related
13 trials

Shared therapeutic areas:

Schizophrenia
Similarity Score10%

Scott W Woods, MD

Yale University

Related
9 trials

Shared therapeutic areas:

Schizophrenia
Similarity Score10%

Jean-Olivier ARNAUD, Director

Assistance Publique Hôpitaux de Marseille

Related
17 trials

Shared therapeutic areas:

Schizophrenia
Similarity Score10%

Nancy A Rigotti, MD

Massachusetts General Hospital

Related
9 trials

Shared therapeutic areas:

Tobacco Use Disorder
Similarity Score10%

Urielle Desalbres

Assistance Publique Hôpitaux de Marseille

Related
71 trials

Shared therapeutic areas:

Schizophrenia
Similarity Score10%

Nobuhito Sanada

Otsuka Pharmaceutical Co., Ltd.

Related
11 trials

Shared therapeutic areas:

Schizophrenia
Similarity Score10%

Dorothy Hatsukami, PhD

University of Minnesota

Related
13 trials

Shared therapeutic areas:

Tobacco Use Disorder

Worked with same sponsors:

Brown UniversityNational Institute on Drug Abuse (NIDA)
Similarity Score10%

Walter Ling, M.D.

Friends Research Institute, Inc.

Related
28 trials

Shared therapeutic areas:

Tobacco Use Disorder

Worked with same sponsors:

National Institute on Drug Abuse (NIDA)
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT00136760Phase 2PrincipalInvestigator

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

Schizophrenia and Disorders With Psychotic FeaturesTobacco Use Disorder
Completed
NCT00218218Phase 2PrincipalInvestigator

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

SchizophreniaSchizophrenia and Disorders With Psychotic FeaturesTobacco Use Disorder
Completed
NCT00218231Phase 2PrincipalInvestigator

Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

SchizophreniaTobacco Use Disorder
Completed

All 3 trials loaded